Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.
about
Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumoniaInfluenza vaccination in immunocompromised patients: efficacy and safety.Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.Immunologic consequences of chemotherapy for acute myeloid leukemia.A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation.European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN.Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.Seasonal influenza vaccine in immunocompromised persons.
P2860
Q28732374-9F41E915-B388-4111-BA3B-401E2816AB83Q30358640-C085020E-C289-48FB-BB2F-852517F0CFCDQ30373149-1C56CB7C-51F1-41BE-9382-00893F050283Q30413413-5DE32E21-85DF-46F4-8EC3-059A736047ABQ35846308-01C12CDE-9665-4866-8AE1-9EEA8A63525BQ36478891-CF950274-14A8-4045-A316-7A806E5594ABQ36781782-20676D36-C755-425B-B33F-C3D3CA7A4055Q38077827-44DAB4E7-00C3-4D74-91CE-8EBB9A7BF8F0Q38269154-1A49E53C-26B8-4AFF-8035-4CC632181E06Q40306881-E34482C4-1537-42B1-9D12-07A4EEE77AA9Q40413531-5E38DC67-3452-48FF-9007-489630DA6F3DQ54265837-69EFD371-0C72-45AE-BC36-A17F2AE51127
P2860
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Graft-versus-host disease is t ...... em cell transplant recipients.
@ast
Graft-versus-host disease is t ...... em cell transplant recipients.
@en
type
label
Graft-versus-host disease is t ...... em cell transplant recipients.
@ast
Graft-versus-host disease is t ...... em cell transplant recipients.
@en
prefLabel
Graft-versus-host disease is t ...... em cell transplant recipients.
@ast
Graft-versus-host disease is t ...... em cell transplant recipients.
@en
P2093
P2860
P1433
P1476
Graft-versus-host disease is t ...... em cell transplant recipients.
@en
P2093
Bilal Mohty
Blood and Marrow Transplant Program
Christophe Combescure
Eddy Roosnek
Emmanuel Levrat
Geneva University Hospitals H1N1 study group
Jakob Passweg
Laurent Kaiser
Marija Vukicevic
Michael Bel
P2860
P304
P356
10.3324/HAEMATOL.2011.040386
P577
2011-03-21T00:00:00Z